Endo has been fighting off a generic from Eagle Pharmaceuticals since 2018, when it sued Eagle after the FDA approved its Vasostrict generic. Endo's drug is distributed by its unit Par ...

Eagle Pharmaceuticals isn’t leaving M&A to larger birds of prey in the biopharma kingdom, swooping down to take a piece of Enalare Therapeutics and its lead asset, ENA-001. The cost for Eagle to ...